cancer-gi-cancer-digestive-2018-scientifictracks

12 / 30

Page 44
Notes:
Journal of Gastrointestinal & Digestive System | ISSN: 2161-069X | Volume: 8
&
&
October 29-30, 2018 | San Francisco, USA
International Conference on
Gastrointestinal Cancer and Therapeutics
4th World Congress on
Digestive & Metabolic Diseases
26th Annual Congress on
Cancer Science and Targeted Therapies
Early colorectal cancer detection employing XNA technology
Michael J Powell
DiaCarta Inc., USA
S cientists at DiaCarta have developed an innovative xeno nucleic acid molecular clamp technology, or XNA technology,
to address the sensitivity needs for tumor gene mutation and other important gene mutations in liquid biopsy and FFPE
samples. XNA technology uses proprietary designed XNA oligomers with modified backbones that hybridize target DNA
sequences of interest byWatson-Crick base pairing. When the sequence is a completematch, XNAs hybridize tightly to the DNA
target sequences, blocking strand elongation by DNA polymerase in the PCR reaction. However, when a mutation is present in
the target sequence, the mismatch leads to instability of the XNA oligomer: DNA duplex, allowing strand elongation by DNA
polymerase. As a result, an only target sequence containing mutations is selected for amplification and wild-type sequence,
despite being present in much larger DNA amounts/copies, will not be amplified. Since XNA oligomers are not recognized by
DNA polymerases, they cannot serve as primers in the subsequent real-time PCR reactions. XNA molecular clamps assays are
highly sensitive using nucleic acids obtained from liquid biopsy or tumor tissue biopsy (FFPE) samples. The limit of detection
(LOD) can reach as low as 0.1% (7 or 8 copies of mutant DNA) in 5ng of ctDNA, roughly equivalent to 2ml of blood from a
patient. Since the presence of high levels of circulating cell-free mutant tumor DNA (ctDNA) and exosome derived nucleic
acids have been found to be associated with poor survival in colorectal and other cancers and dynamic monitoring of the level
can be used as a predictive factor for cancer treatment.
Biography
Michael J Powell is a highly recognized scientific and business leader with more than 25 year’s experience in R&D, technology, and business and corporate
development. He has extensive knowledge and experience in the fields of molecular diagnostic assay research and development, qPCR and other nucleic acid
amplification technologies, and automated instrumentation platforms. He has published many research papers in leading scientific journals and holds more than 40
patents and patent-pending applications. He received his PhD in medicinal organic chemistry from Loughborough University, Loughborough, UK and also pursued
postdoctoral research and a teaching fellowship from the University of Nottingham, Nottingham, UK. He was also a Postdoctoral Industrial Research Fellow at
the University of Oxford, UK and was instrumental in developing the amperometric glucose sensing technology that was the basis of Medisense, Inc. which was
acquired by Abbott Labs for $950M.
Michael J Powell, J Gastrointest Dig Syst 2018, Volume 8
DOI: 10.4172/2161-069X-C8-085